WuXi AppTec 4/27/2026 Earnings Report

WuXi AppTec EPS Results

• Actual EPS: $0.23
• Consensus EPS: $0.18
• Beat/Miss: Beat by +$0.05
• One Year Ago EPS: N/A

WuXi AppTec Revenue Results

• Actual Revenue: $1.82 billion
• Expected Revenue: $1.59 billion
• Beat/Miss: Beat by +$229.45 million
• YoY Revenue Growth: N/A

WuXi AppTec Announcement Details

• Date: 4/27/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

WuXi AppTec (OTCMKTS:WUXAY) is a global contract research, development and manufacturing organization serving the pharmaceutical, biotechnology and medical device industries. Headquartered in Shanghai and founded in 2000, the company provides end-to-end solutions that span drug discovery, development and manufacturing. Its offerings enable customers to accelerate the research and development process for small molecules, biologics, cell and gene therapies, as well as medical devices.

Key services include chemistry and biology discovery support, preclinical safety assessment, analytical and formulation development, clinical manufacturing, large-scale biomanufacturing, and quality testing. The company also offers specialized platforms in areas such as genomics, cell therapy, antibody development, regulatory consulting and medical device testing, with the aim of integrating advanced technologies to streamline project workflows and reduce time to clinic.

With operations across China, North America, Europe and Asia-Pacific, WuXi AppTec works with multinational pharmaceutical and biotech companies, academic institutions and emerging innovators. The company was founded by Dr. Ge Li, who continues to guide its strategic growth and investment in research infrastructure. By combining end-to-end capabilities with a global footprint, WuXi AppTec positions itself as a one-stop partner for advancing life science discovery and manufacturing worldwide.